Compare GSK plc (GSK) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? GSK plc trades at $50.36 (market cap $102.60B), while Vanguard S&P 500 Growth Index Fund ETF trades at $85. The key difference: GSK plc pays a 3.57% dividend while Vanguard S&P 500 Growth Index Fund ETF pays none, and Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| GSK | VOOG | |
|---|---|---|
Market Cap | $102.60B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $61.18 | $85.42 |
52-Week Low | $38.22 | $65.32 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
VOOG trades at $85.05, down 0.18% on the day but near 52-week highs, with a bullish technical signal from moving averages and a neutral oscillator stance. Recent news highlights institutional accumulation and strong growth ETF comparisons, though RSI levels suggest potential overbought conditions. The fund focuses on large-cap growth stocks with low expense ratios, benefiting from tech sector leadership.
Outlook remains positive due to institutional inflows and growth exposure, but risks include tech concentration and market volatility. The fund's low costs and historical performance support long-term growth appeal, though investors should monitor valuation metrics amid elevated levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
